2025 年 11 月 6 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說明 | | 交易性質 | 買入／賣出 | 涉及的股份 | 已支付／已收取 | 已支付或已收 | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 總數 | 的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | （H） | （L） | | J.P. Morgan | 2025 | 年 11 | 月 | 其他類別的證券 | | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 賣出 | 4,000 | $36,210.0000 | $9.0525 | $9.0525 | | Securities | 5 日 | | | (例如: | 股權互換) | 產生的 Delta 1 產品的對沖活動 | | | | | ...

透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說 | 交易性質 | | 買入／賣出 | 涉及的股份總 | | 已支付／已收 | 已支付或已收 | 已支付或已收 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | | | 數 | | 取的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | | | | （H） | （L） | | | J.P. Morgan | 2025 | 年 11 | 月 4 | 其他類別的證 | | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 賣出 | | 1,000 | $9,040.0000 | $9.0400 | | $9.0400 | | Securities | 日 | | | (例如: 券 | 股權 產生的 | Delta 1 產品的對沖活動 ...

2025 年 11 月 5 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說明 | 產品說明 | 交易性質 | 與衍生工具有關 | | 到期日或清結日 | | 參考價 | | 已支付／已收 | 交易後數額（包括 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 的參照證券數目 | | | | | | 取的總金額 | 與其訂有協議或 | | | | | | | | | | | | | | | | 達成諒解的任何 | | | | | | | | | | | | | | | | 人士的證券） | | J.P. Morgan | 2025 | 年 11 | 月 4 | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | | 1,000 | 2027 年 9 24 | 月 | | $9.0274 | $9 ...

Group 1 - As of November 5, 48 stocks reached their 52-week highs, with the top three being Eder Investment Holdings (06182) at 40.63%, LFG Investment Holdings (03938) at 11.70%, and Tianrui Automotive Interior (06162) at 11.11% [1] - Eder Investment Holdings closed at 0.900 and reached a high of 1.350, reflecting a significant increase [1] - LFG Investment Holdings and Tianrui Automotive Interior also showed notable increases in their stock prices, indicating positive market sentiment towards these companies [1] Group 2 - The report also highlights stocks that reached their 52-week lows, with XL South Strategy - U (4.034) showing the largest decline at -23.33% [2] - Other notable declines include Minglue Technology - W (197.900) at -21.01% and Zhihua Holdings (0.039) at -19.15%, indicating potential challenges faced by these companies [2] - The data suggests a mixed market environment, with some companies performing well while others struggle to maintain their stock prices [2] Group 3 - The report includes various stocks with minor declines, such as Capital World Financial (0.570) at -3.45% and Hu Shang Ayi (84.550) at -3.37%, reflecting a slight downward trend in certain sectors [3] - The overall performance of these stocks indicates a cautious market sentiment, with investors closely monitoring fluctuations [3] - The presence of both high-performing and underperforming stocks suggests a diverse investment landscape, requiring careful analysis for potential opportunities [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公司名稱: 康基醫療控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09997 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,0 ...

就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | 有關證券的說明 | | 交易性質 | 買入／賣出 | 涉及的股份 | 已支付／已收取 | 已支付或已收 | 已支付或已收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 總數 | 的總金額 | 取的最高價 | 取的最低價 | | | | | | | | | | | （H） | （L） | | J.P. Morgan | 2025 | 10 年 月 | 其他類別的證券 | | 因全屬客戶主動發出且由客戶需求帶動的買賣盤所 | 賣出 | 2,500 | $22,532.8300 | $9.0300 | $9.0200 | | Securities | 31 日 | | (例如: | 股權互換) | 產生的 Delta 1 產品的對沖活動 | | | | | | | PLC | | | | 其他類別的證券 | 因全屬客戶主動發出且由客戶需求帶動 ...

完 註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的 | 產品說明 | 交易性質 | 與衍生工具 | 到期日或清結日 | | | 參考價 | 已支付／已收取 | 交易後數額（包括 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 說明 | | | 有關的參照 | | | | | 的總金額 | 與其訂有協議或 | | | | | | | | | 證券數目 | | | | | | 達成諒解的任何 | | | | | | | | | | | | | | | 人士的證券） | | J.P. Morgan | 2025 | 年 10 月 | 31 日 | 衍生工具 | 其他類別產品 | 發行衍生工具 | 92,5 ...

Core Viewpoint - 康基医疗控股有限公司 is set to be delisted from the Hong Kong Stock Exchange if the privatization proposal conditions are met or exempted, with the removal from the Hang Seng Composite Index and its classification indices effective after market close on November 11, 2025 [1]. Group 1 - 康基医疗 will be removed from the Hang Seng Composite Index and its classification indices, including the Hang Seng Healthcare Index, effective November 12, 2025 [4]. - The delisting is contingent upon the fulfillment or exemption of conditions related to the privatization proposal [1].

Core Points - The Hong Kong Stock Exchange announced that Kangji Medical Holdings Limited (stock code: 09997) will be delisted if the privatization proposal conditions are met or exempted [1] - Kangji Medical will be removed from the Hang Seng Composite Index and its classification indices after the market closes on November 11, 2025, based on the closing price of that day [1] Index Removal Details - Kangji Medical will be excluded from the following indices: - Hang Seng Composite Index [4] - Hang Seng Composite Small Cap Index [4] - Hang Seng Composite Mid and Small Cap Index [4] - Hang Seng Industry Index - Healthcare [4] - The changes will take effect on November 12, 2025 [1][4]

2025 年 10 月 31 日 完 註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易是為本身帳戶進行的。 J.P. Morgan Securities PLC 是最終由 JPMorgan Chase & Co.擁有的公司。 交易披露 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說 | 產品說明 | 交易性質 | 與衍生工具有 | 到期日或清結 | | 參考價 | 已支付／已收取 | 交易後數額（包 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | | 關的參照證券 | 日 | | | 的總金額 | 括與其訂有協議 | | | | | | | | | 數目 | | | | | 或達成諒解的任 | | | | | | | | | | | | | | 何人士的證券） | ...